Journals Why Publish With Us? Author information Article notes Copyright and License information Disclaimer. Etzel, Reginald F. This series does not attempt to completely list all the recent progress in SCLC research that has been well covered elsewhere in recent reviews. Join the conversation about this journal. To submit a manuscript or to learn more about the JTO, please visit jto. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. Philip A. This indicator counts the number of citations received by documents from a journal and divides them by the total number of documents published in that journal.
IASLC > International Association for the Study of Lung Cancer > About IASLC > News Detail
Lung Cancer International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to all. Lung Cancer is an international publication covering the clinical, translational Lung Cancer has a Journal Impact Factor* ofranking it 12 of 63 in.
DENVER – The International Association for the Study of Lung Cancer (IASLC) announces a significant jump in the Impact Factor of the.
Paul Hofman. Nobel, Prasad S. Torre, Ahmedin Jemal.
The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces.
RECTOSCOPIA PREPARACION DE LASAGNA
|It is used to measure the importance or rank of a journal by calculating the times its articles are cited.
Friedberg, Julie Brahmer, Jamie Chaft.
Video: Lung cancer international impact factor The Pathophysiology of Non-small Cell Lung Cancer
Proton therapy is not expected to be uniformly superior for all patients in all scenarios, but it is expected to provide dosimetric advantages that translate into superior clinical outcomes for the right patient, at the right time.
Pacheco, Drew Moghanaki. In the rapidly evolving landscape of emerging biomarkers for immunotherapy, tumor mutational burden TMB is very promising as a predictive biomarker and potentially could lead the way for precision immuno-oncology.
This indicator counts the number of citations received by documents from a journal and divides them by the total number of documents published in that journal. The book Lung Cancer is now available both online and in print with English and Chinese version.
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer. The First Impact Factor for Translational Lung Cancer Research: The impact factor, as published in the annual Journal Citation Reports (JCR), Translational Lung Cancer Research is an international, peer-reviewed.
Berry, Thomas A.
Lung Cancer Management
Adusumilli, Daniela Molena. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. This focused issue is organized to provide a clear update on pleural and peritoneal mesothelioma, to stimulate further research and hopefully, to provide a better outcome for patients with this still dreadful disease. Hussein Elkhayat, Diego Gonzalez-Rivas.